Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 1;22(3):162-171.
doi: 10.2459/JCM.0000000000001108.

Updated clinical evidence and place in therapy of bempedoic acid for hypercholesterolemia: ANMCO position paper

Furio Colivicchi  1 , Stefania Angela Di Fusco  1 , Pietro Scicchitano  2 , Pasquale Caldarola  3 , Adriano Murrone  4 , Serafina Valente  5 , Stefano Urbinati  6 , Loris Roncon  7 , Vincenzo Amodeo  8 , Nadia Aspromonte  9 , Manlio Cipriani  10 , Stefano Domenicucci  11 , Giuseppina Maura Francese  12 , Massimo Imazio  13 , Fortunato Scotto di Uccio  14 , Andrea Di Lenarda  15 , Michele Massimo Gulizia  12   16 , Domenico Gabrielli  17
Affiliations
Review

Updated clinical evidence and place in therapy of bempedoic acid for hypercholesterolemia: ANMCO position paper

Furio Colivicchi et al. J Cardiovasc Med (Hagerstown). .

Abstract

The central role of high low-density lipoprotein cholesterol levels in atherosclerotic cardiovascular disease has led to research focused on lipid-lowering agents for cardiovascular risk reduction. Bempedoic acid is an emerging treatment for hypercholesterolemia that has recently been approved for marketing in the United States and Europe. This review focuses on its mechanism of action and summarizes the main preclinical study findings. Furthermore, we report the clinical evidence supporting and guiding its use in hypercholesterolemia management.

PubMed Disclaimer

Comment in

References

    1. World Health Organization. Available at: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases... . [Accessed 18 August 2020]
    1. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017; 38:2459–2472.
    1. Mach F, Baigent C, Catapano AL, et al. ESC Scientific Document Group.. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2019; 41:111–188. doi: 10.1093/eurheartj/ehz455. - DOI
    1. Cannon CP, Blazing MA, Giugliano RP, et al. IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372:2387–2397.
    1. Sabatine MS, Giugliano RP, Keech AC, et al. FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376:1713–1722.

MeSH terms

LinkOut - more resources